Table 2.
Efficacy outcomes in short-duration trials (4 to 12 weeks) of pharmacotherapies for overactive bladder
| Incontinence episodes /24 h | 3-day 0 incontinence | Urgency episodes /24 h | Micturitions /24 h | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Studies | Baseline (mean)a | Change from baseline | MD (95% CI; I2) | No. of studies | RR (95% CI; I2) | No. of studies | Baseline (mean)a | Change from baseline | MD (95% CI; I2) | No. of studies | Baseline (mean)a | Change from baseline | MD (95% CI; I2) | |
| Mirabegron 50 mg + solifenacin 5 mg vs. solifenacin 5 mg | 4 | 3.17 | −1.84 vs. −1.63 | −0.18 (−0.31, −0.05; I2 = 0%) | 3 | 1.23 (1.13, 1.34; I2 = 0%) | 4 | 6.21 | −3.34 vs. −2.73 | −0.58 (−0.89, −0.28; I2 = 59%) | 4 | 10.28 | −2.20 vs. −1.69 | −0.41 (−0.54, −0.27; I2 = 0%) |
| Mirabegron 50 mg + solifenacin 5 mg vs. mirabegron 50 mg | 3 | 3.14 | −1.85 vs. −1.56 | −0.34 (−0.52, −0.16; I2 = 8%) | 2 | 1.18 (0.98, 1.41; I2 = 22%) | 3 | 6.38 | −3.47 vs. −2.73 | −0.77 (−1.02, −0.52; I2 = 0%) | 3 | 10.78 | −2.41 vs. −1.94 | −0.56 (−0.75, −0.37; I2 = 0%) |
| Mirabegron 50 mg vs. solifenacin 5 mg | 4 | 2.85 | −1.51 vs. −1.70 | +0.20 (0.02, 0.38; I2 = 12%) | 3 | 1.01 (0.93, 1.09; I2 = 0%) | 4 | 6.75 | −3.76 vs. −3.94 | +0.19 (−0.14, 0.52; I2 = 52%) | 4 | 10.97 | −2.47 vs. −2.64 | +0.18 (0.01, 0.35; I2 = 0%) |
| Mirabegron 50 mg vs. tolterodine ER 4 mg | 5 | 2.50 | −1.28 vs. −1.16 | −0.12 (−0.26, 0.03; I2 = 0%) | 4 | 1.01 (0.92; 1.11; I2 = 0%) | 5 | 5.33 | −1.90 vs. −1.88 | −0.01 (−0.19, 0.17; I2 = 0%) | 6 | 11.43 | −1.70 vs. −1.52 | −0.18 (−0.43, 0.06; I2 = 60%) |
| Fesoterodine 8 mg vs. tolterodine ER 4 mg | 3 | NR | −1.90 vs. −1.69 | −0.18 (−0.29, −0.07; I2 = 10%) | 2 | 1.10 (1.04, 1.16; I2 = 0%) | 3 | 9.87 | −3.68 vs. −3.14 | −0.40 (−0.69, −0.12; I2 = 0%) | 3 | NR | −2.35 vs. −2.14 | −0.22 (−0.43, −0.01; I2 = 0%) |
| Solifenacin 5 mg vs. tolterodine 4 mg | 4 | 2.71 | −1.56 vs. −1.25 | −0.36 (−0.58, −0.13; I2 = 30%) | 0 | NR | 4 | 5.53 | −2.77 vs. −2.26 | −0.49 (−0.79, −0.20; I2 = 0%) | 4 | NR | −2.35 vs. −2.14 | −0.20 (−0.45, 0.05; I2 = 0%) |
| Solifenacin 5 mg vs. oxybutynin IR 15 mg | 0 | NR | NR | NR | 0 | NR | 1 | 6.45 | −2.65 vs. −3.70 | +1.05 (−0.55, 2.65; I2 = NA) | 1 | NR | −2.3 vs. −3.1 | +0.80 (−0.43, 2.03; I2 = NA) |
| Tolterodine vs. oxybutynin | 8 | 5.06 | −3.00 vs. −3.26 | +0.01 (−0.25, 0.28; I2 = 57%) | 1 | 0.73 (0.55, 0.97; I2 = NA) | 0 | NR | NR | NR | 8 | NR | −2.61 vs. −2.72 | −0.16 (−0.49, 0.18; I2 = 30%) |
Note: bold indicates statistically significant
Abbreviations: CI, confidence interval; ER, extended release; h, hour; IR, immediate release; MD, mean difference; NA, not applicable; NR, not reported; RR, risk ratio
aMean at baseline calculated for studies with available data